We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01582152
Recruitment Status : Terminated (Phase 2 part of the trial will no longer continue since the protocol competes with another TPI287 protocol in outside institution supported by the sponsor.)
First Posted : April 20, 2012
Results First Posted : June 5, 2019
Last Update Posted : June 5, 2019
Cortice Biosciences, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma. The goal of Part II is to learn if TPI 287 when given with bevacizumab can help to control glioblastoma better than when bevacizumab is given alone. The safety of the drug combination will also be studied.

TPI 287 is similar to a type of chemotherapy drug called a taxane and is designed to block a protein (tubulin) that helps the cancer cells divide. By blocking the tubulin, the drug may be able to cause the cancer cells to shrink or stop growing.

Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.

Condition or disease Intervention/treatment Phase
Brain Neoplasms Central Nervous System Neoplasms Drug: TPI287 Drug: Bevacizumab Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma
Study Start Date : July 2012
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: TPI 287 + Bevacizumab

Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.

Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.

Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I.

Drug: TPI287

Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.

Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.

Drug: Bevacizumab
Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
Other Names:
  • Avastin
  • Anti-VEGF Monoclonal Antibody
  • rhuMAb-VEGF

Experimental: Bevacizumab Group

Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.

Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone.

Drug: Bevacizumab
Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
Other Names:
  • Avastin
  • Anti-VEGF Monoclonal Antibody
  • rhuMAb-VEGF

Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: PFS will be evaluated as a continuous variable, up to one year ]
    Progression free survival (PFS) measured from time of registration until date of progression or death (whichever is earlier) (event time) or last date participant was known to be alive without progression (censoring time).

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 1 year ]
    ORR is number participants who experience complete response (CR) or partial response (PR) analyzed for completion of at least one cycle in all treatment arms, including exploratory treatment arm. CR requires: 1) complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks; 2) no new lesions; 3) stable or improved non-enhancing (T2/FLAIR) lesions; 4) off corticosteroids (or on physiologic replacement doses only); 5) stable or improved clinically. Partial response (PR) requires: 1) >50% decrease compared with baseline in sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; 2) No progression of non-measurable disease; 3) No new lesions; 4) Stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; 5) corticosteroid dose at time of scan should be < dose at baseline scan; 6) Improved or stable clinically

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically proven glioblastoma or gliosarcoma to be eligible for this protocol. Patients will be eligible if the original histology was low-grade glioma or anaplastic glioma (WHO II or III) and a subsequent histological diagnosis of glioblastoma or gliosarcoma is made. Only patients with histologically proven or imaging proven recurrent glioblastoma or gliosarcoma will be eligible for this protocol.
  2. Patients must have shown unequivocal evidence for tumor recurrence or progression by MRI scan and should have failed radiation and temozolomide therapy. The scan done prior to study entry documenting progression will be reviewed by the treating physician to document changes in tumor dimension to confirm recurrence. Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis.
  3. For this study, patients may have had up to 2 prior relapses provided the functional status and other eligibility criteria for enrollment are met.
  4. All patients must sign an informed consent indicating their awareness of the investigational nature of this study in keeping with the policies of this hospital.
  5. The baseline on-study MRI should be performed within 14 days (+/- 3 working days) prior to registration and on a steroid dosage that has been stable or decreasing for at least 5 days. If the steroid dose is increased between the date of imaging and the initiation of therapy (or at that time), a new baseline MRI is required. The same type of scan, i.e., MRI, must be used throughout the period of protocol treatment for tumor measurement.
  6. Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply: a) At least 4 weeks have elapsed from the date of surgery and the patients have recovered from the effects of surgery. b) Evaluable or measurable disease following resection of recurrent tumor is not mandated for eligibility into the study. c) To best assess the extent of residual measurable disease post-operatively, a MRI should be done no later than 96 hours in the immediate post-operative period.
  7. Patients must be 18 years old or older.
  8. Patients must have a Karnofsky performance status (KPS) equal or greater than 60.
  9. Patients must have recovered from the toxic effects of prior therapy to < grade 2 toxicity per CTC version 4 (except deep vein thrombosis) prior to Day 1 of Cycle 1: a) at least 12 weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission computed tomography (PET) scan in which case at least 4 weeks from completion of radiation therapy will suffice (Note: for patients who have undergone surgery to confirm recurrence after radiation therapy, guidelines in 5.2.6a should be followed). b) 4 weeks from prior cytotoxic therapy. c) 4 weeks from prior experimental drug. d) 2 weeks from vincristine.
  10. 9) (continued) e) 6 weeks from nitrosoureas. f) 3 weeks from procarbazine administration. g) 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not count). h) Patients who receive anticancer agents for non-therapeutic purposes unrelated to this study (such as presurgically for obtaining pharmacology data for the agent) will be eligible to enter the study provided they have recovered from the toxic effects of the agent if any. i) Any questions related to the definition of non-cytotoxic agents should be directed to the Study Chair.
  11. Patients must have adequate bone marrow function (ANC> 1,500/mm3 and platelet count of > 100,000/mm3), adequate liver function (SGPT < 3 times upper limit normal and alkaline phosphatase < 2 times upper limit normal, total bilirubin <1.5 mg/dl), and adequate renal function (BUN and creatinine <1.5 times institutional normal) prior to starting therapy.
  12. Male patients on treatment with TPI 287 must agree to use an adequate method of contraception for the duration of the study, and for 30 days after the last dose of study medication. Women of childbearing potential must not be pregnant (as evidenced by a negative pregnancy test prior to study entry), must not be breast-feeding and must practice adequate contraception for the duration of the study, and for 30 days after the last dose of study medication. An adequate method of contraception is one highly effective method or more than one additional methods. Highly effective methods include intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation and partner's vasectomy. Additional effective methods include latex condom, diaphragm and cervical cap.
  13. Patient must be able to tolerate the procedures required in this study including periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study.
  14. Exploratory, Cross-Over Trial Arm: Patients with evidence of clinical or radiographic progression on the bevacizumab alone arm are eligible for cross-over into the exploratory arm of the trial if KPS is 50 or greater and all other criteria for initial enrollment in the trial are still met at time of progression. Patients will be excluded if the investigators feel the patient will not tolerate TPI 287 or if an alternative treatment approach is deemed necessary by the treating physician.

Exclusion Criteria:

  1. Inability to comply with protocol or study procedures.
  2. Prior treatment with bevacizumab or TPI 287.
  3. Patients who are receiving concurrent Enzyme-Inducing Anti-Epileptic Drugs (EIAEDs) (e.g., carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital and primidone, or who received EIAEDs within 2 weeks prior to the first dose of study drug.
  4. Patients who have received more than one course of radiation therapy or more than a total dose of 65 Gy. Patients may have received radiosurgery as part of the initial therapy (i.e., in addition to one course of radiation therapy); however, the dose used for the radiosurgery counts against the total dose limit listed above.
  5. Patient who have received prior taxane chemotherapy for treatment of GBM or other malignancy. GliadelTM as part of the initial therapy is permitted. Patients who have received prior biologic therapy other than bevacizumab will be eligible.
  6. Any condition, including the presence of clinically significant laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. These would include: a) Active infection including known AIDS or Hepatitis C or with a fever >/= 38.5°C within 3 days prior to the study enrollment. b) Diseases or conditions that obscure toxicity or dangerously alter drug metabolism. c) Serious intercurrent medical illness (e.g. symptomatic congestive heart failure).
  7. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from providing informed consent.
  8. Inadequately controlled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg)
  9. Prior history of hypertensive crisis or hypertensive encephalopathy
  10. New York Heart Association (NYHA) Grade II or greater congestive heart failure.
  11. History of myocardial infarction or unstable angina within 6 months prior to Day 1
  12. History of stroke or transient ischemic attack within 6 months prior to Day1
  13. Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
  14. History of hemoptysis (>/= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
  15. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  16. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study.
  17. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
  18. History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
  19. Serious, non-healing wound, active ulcer, or untreated bone fracture.
  20. Proteinuria as demonstrated by: (1) Urine protein:creatinine (UPC) ratio >/= 1.0 at screening; OR (2) Urine dipstick for proteinuria >/= 2+ (patients discovered to have >/= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate </= 1g of protein in 24 hours to be eligible).
  21. Known hypersensitivity to any component of bevacizumab
  22. Pregnancy (positive pregnancy test) or lactation. Not able to use of effective means of contraception (men and women) in subjects of child-bearing potential.
  23. Patients with Grade 2 or higher peripheral neuropathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01582152

Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Cortice Biosciences, Inc.
Layout table for investigator information
Principal Investigator: W K Alfred Yung, MD, BS M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01582152    
Other Study ID Numbers: 2011-0705
NCI-2012-00846 ( Registry Identifier: NCI CTRP )
First Posted: April 20, 2012    Key Record Dates
Results First Posted: June 5, 2019
Last Update Posted: June 5, 2019
Last Verified: May 2019
Keywords provided by M.D. Anderson Cancer Center:
Recurrent Glioblastoma
Glioblastoma multiforme
Brain Neoplasms
Central Nervous System Neoplasms
Anti-VEGF Monoclonal Antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors